
News|Articles|October 12, 2023
How to Avoid Last-Minute CMC Roadblocks to Approval (Oct 2023)
Author(s)Societal CDMO
Problems can arise when sponsors face balancing available budget and time resources between clinical and chemistry, manufacturing, and controls (CMC) needs. Because of their high-profile importance in development, clinical needs get the emphasis, while the many CMC needs and risks may seem less critical. Unfortunately, as time passes, there is an increased risk of CMC issues becoming more complicated, time-consuming, and expensive to fix. Learn how to avoid these roadblocks by reading this white paper from Societal™ CDMO.
Trending on Pharmaceutical Technology
1
GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing
2
Ask the Expert: Complying with Standards
3
How the Nitrosamine Guidance Shift is Changing LC-MS Workflows for APIs and Peptides
4
Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models
5